VRTXON

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Navn VRTXON

Rangering No.3622

Markedsverdi $0.00

Fullt utvannet markedsverdi $0.00

Markedsandel %

Handelsvolum/markedsgrense (24 timer) 17,906,142.52%

Opplagsforsyning 4.00949604

Maksimal forsyning 0

Total forsyning 4.00949604

Opplagsforsyning %

Utstedelsesdato --

Prisen for aktivaen da den først ble utstedt --

All-time high 466.35223147502205, 2026-03-26

Laveste pris 414.92035330237934, 2026-05-05

Offentlig blokkjede VRTXON

Introduksjon Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Sektor

Sosiale medier

• Twitter

• Offisiell nettside
• Blokker Explorer

Fondsstrømanalyse

etfindex:mc_etfindex_source Ansvarsfraskrivelse: Dataene leveres av cmc og bør ikke betraktes som investeringsråd.